A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Clinical trial NCT07518173 · RECRUITING
Trial details
- NCT number
- NCT07518173
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-21
- Primary completion
- 2029-12-01
- Enrollment
- 596
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.